Pandemic good news
September 19, 2022
351,232
14,171
2,377
4.71%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Dr John Campbell Episodes Around September 19, 2022
See what was published immediately before and after this episode.
9:41Now PlayingPandemic good news
YouTube Description
as posted by the channelCDC variant report
Some increase in BA.4.6 and BA.2.75
BA.4.6
Progressive US increase, starting to slowly displace BA.5
US of America (9,526)
Canada (1,007)
Denmark (500)
France (400)
Australia (288)
Germany (248)
Chile (242)
Dominican Republic (173), Peru (149), Luxembourg (123), Belgium (102), Israel (101), Italy (94), Ireland (93), Sweden (92), Spain (85), Netherlands (84), Brazil (76), Argentina (68), Japan (67), New Zealand (60), Switzerland (54), Puerto Rico (53), South Africa (53), Ecuador (49), Mexico (35), Colombia (34), Trinidad and Tobago (30), Czech Republic (27), Costa Rica (23), Jamaica (21), Portugal (20), South Korea (19), Austria (17), Botswana (17), Indonesia (13), Sint Maarten (12), Senegal (11)
BA.2.75
Some US increase
Growth rate is currently 61% per week relative to co-circulating lineages
Current US nowcast
BA.5 84.8% (UK, 87.2%)
BA.4.6 10.3% (UK, 3.3)
BA.4 1.8%
BF.7 1.7%
BA.2.75 1.3% (UK, 1.6%)
BA.2 0% (UK, 0.5%)
BA.1s 0%
Delta 0%
Others 0% (UK, 2.4%)
XE 0%
UK, technical briefing 45
(September 2022)
Contains early data and analysis on emerging variants
Findings have a high level of uncertainty
Data cut-off of 5 September 2022
BA.5
BA.5 is the predominant circulating variant in the United Kingdom
Newly designated variant – V-22SEP-01 (BA.4.6)
Omicron sub-lineage BA.4.6
An apparent small growth advantage relative to BA.5.
BA.4.6 represented 3.31% of UK samples
Preliminary neutralisation data from BA.4.6
Expect some immune escape from BA.4 or BA.5 antibodies
There is NO increased risk of hospital admission after BA.4 or BA.5 infection compared to BA.2 infection.
Expect some immune escape triple dosed recipients of the Pfizer BNT162b2 vaccine.
V-22JUL-01 (BA.2.75)
As of 6 September 2022
BA.2.75 in the UK, 1.6%
Does seem to have growth advantage over co-circulating lineages of,
61% per week
Two sub-lineages of BA.2.75 (BA.2.75.1 and BA.2.75.2) are currently being assessed
BA.4/BA.5 Severity
A case-control study
Risk of being admitted to hospital as an inpatient
Among people presenting to emergency care within 14 days of positive test.
Comparison, risk of admission with BA.4 or BA.5 versus BA.2
Between 16 March 2022 and 23 August 2022
BA.4 n = 2,530
BA.5 n = 12,026
BA.2 n = 17,022
Adjusted for age, sex, vaccination status, week of test, 2 days of extreme heat
There was no difference in the risk of admission between people infected with BA.4 compared to BA.2
There was no difference in the risk of admission between people infected with BA.5 compared to BA.2
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.